Lotery A, Sivaprasad S, O'Connell A, et al. - A randomized, double-blind, placebo-controlled trial was designed to investigate whether eplerenone was superior to placebo in terms of improving visual acuity in individuals with chronic central serous chorioretinopathy (CSCR). A total of 114 individuals were assigned randomly to receive either eplerenone or placebo between Jan 11, 2017, and Feb 22, 2018. There were no serious adverse events in the eplerenone group, but in the placebo group, three unrelated serious adverse events were noted (myocardial infarction [anticipated], diverticulitis [unanticipated], and metabolic surgery [unanticipated]). In an individual with chronic CSCR, they found that eplerenone was not superior to placebo for increasing best-corrected visual acuity after 12 months of treatment. Ophthalmologists who recently prescribe eplerenone for CSCR should discontinue this practice.